These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 12138686
1. [Infliximab combined with methotrexate in the treatment of rheumatoid arthritis]. Sfriso P, Botsios C, Ostuni P, Todesco S. Recenti Prog Med; 2002; 93(7-8):416-20. PubMed ID: 12138686 [Abstract] [Full Text] [Related]
2. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805 [Abstract] [Full Text] [Related]
3. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306 [Abstract] [Full Text] [Related]
4. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [Abstract] [Full Text] [Related]
5. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791 [Abstract] [Full Text] [Related]
6. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group. Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439 [Abstract] [Full Text] [Related]
7. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group. Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186 [Abstract] [Full Text] [Related]
8. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group. Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527 [Abstract] [Full Text] [Related]
9. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F. Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004 [Abstract] [Full Text] [Related]
10. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. Caramaschi P, Canestrini S, Biasi D, Carletto A, Scambi C, Scarperi A, Bambara LM. Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995 [Abstract] [Full Text] [Related]
11. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I. J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748 [Abstract] [Full Text] [Related]
12. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O. Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502 [Abstract] [Full Text] [Related]
13. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [Abstract] [Full Text] [Related]
14. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J. Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645 [Abstract] [Full Text] [Related]
15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [Abstract] [Full Text] [Related]
16. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab]. D'Alessandro G, Bianco MR, Politis S, Ferrandina C, Rossi G, Altomare E. Reumatismo; 2006 Dec; 58(1):59-61. PubMed ID: 16639489 [Abstract] [Full Text] [Related]
17. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Pødenphant J, Hansen G, Lindegaard H, de Carvalho A, Østergaard M, Hørslev-Petersen K, CIMESTRA Study Group. Arthritis Rheum; 2006 May; 54(5):1401-9. PubMed ID: 16645967 [Abstract] [Full Text] [Related]
19. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612 [Abstract] [Full Text] [Related]
20. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374 [Abstract] [Full Text] [Related] Page: [Next] [New Search]